Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Leask

Showing results (61-70 of 221) with videos related to

Pageof 23
Sort By:
Expert Opinion on Therapeutic Targets|July 16, 2013
CCN2: a novel, specific and valid target for anti-fibrotic drug interventionAndrew Leask
Expert Opinion on Emerging Drugs|April 27, 2012
Emerging targets for the treatment of sclerodermaAndrew Leask
American Journal of Physiology. Cell Physiology|March 5, 2020
Conjunction junction, what's the function? CCN proteins as targets in fibrosis and cancersAndrew Leask
Journal of Cell Communication and Signaling|March 7, 2009
Trial by CCN2: a standardized test for fibroproliferative disease?Andrew Leask
Journal of Cell Communication and Signaling|April 22, 2009
What's in an intron? CCN1 mRNA splicing in cancerAndrew Leask
Journal of Cell Communication and Signaling|December 8, 2019
Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosisAndrew Leask
Journal of Cell Communication and Signaling|November 20, 2015
Canadian connective tissue conference London, Ontario: an editorialAndrew Leask
Journal of Cell Communication and Signaling|December 4, 2009
Thrombin-induced CCN2 expression as a target for anti-fibrotic therapy in sclerodermaAndrew Leask
Journal of Cell Communication and Signaling|May 16, 2020
Slow train coming: an anti-CCN2 strategy reverses a model of chronic overuse muscle fibrosisAndrew Leask
Matrix Biology : Journal of the International Society for Matrix Biology|November 28, 2025
CCN1: a SASPy protein that plays multifaceted roles in fibrogenesisAndrew Leask
Pageof 23

Showing results (61-70 of 221) with videos related to

Sort By:
Pageof 23
Expert Opinion on Therapeutic Targets|July 16, 2013
CCN2: a novel, specific and valid target for anti-fibrotic drug interventionAndrew Leask
Expert Opinion on Emerging Drugs|April 27, 2012
Emerging targets for the treatment of sclerodermaAndrew Leask
American Journal of Physiology. Cell Physiology|March 5, 2020
Conjunction junction, what's the function? CCN proteins as targets in fibrosis and cancersAndrew Leask
Journal of Cell Communication and Signaling|March 7, 2009
Trial by CCN2: a standardized test for fibroproliferative disease?Andrew Leask
Journal of Cell Communication and Signaling|April 22, 2009
What's in an intron? CCN1 mRNA splicing in cancerAndrew Leask
Journal of Cell Communication and Signaling|December 8, 2019
Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosisAndrew Leask
Journal of Cell Communication and Signaling|November 20, 2015
Canadian connective tissue conference London, Ontario: an editorialAndrew Leask
Journal of Cell Communication and Signaling|December 4, 2009
Thrombin-induced CCN2 expression as a target for anti-fibrotic therapy in sclerodermaAndrew Leask
Journal of Cell Communication and Signaling|May 16, 2020
Slow train coming: an anti-CCN2 strategy reverses a model of chronic overuse muscle fibrosisAndrew Leask
Matrix Biology : Journal of the International Society for Matrix Biology|November 28, 2025
CCN1: a SASPy protein that plays multifaceted roles in fibrogenesisAndrew Leask
Pageof 23